Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Study of Glumetinib in Combination With Osimertinib as 1st Line Treatment in Patients With Non-Small Cell Lung Cancer

16 novembre 2026 aggiornato da: Shanghai JMT-Bio Inc.

A Multicenter, Randomized, Controlled Phase Ⅲ Clinical Study on the Efficacy and Safety of Glumetinib in Combination With Osimertinib as First-Line Treatment in Patients With Non-Small Cell Lung Cancer With Classic EGFR Mutations and MET Overexpression or Amplification

To evaluate the efficacy and safety of Glumetinib plus Osimertinib in patients with non-small cell lung cancer with classic EGFR mutations and MET overexpression or amplification.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Stimato)

375

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Clinical Trials Information Group officer
  • Numero di telefono: 031169085587
  • Email: ctr-contact@cspc.cn

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 75 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Able to understand and willingness to voluntarily provide written informed consent.
  2. Age 18 to 75 years, males or females.
  3. Patientsconfirmed unresectable locally advanced or metastatic NSCLC patients;.
  4. Ability to provide qualified tumor samples..
  5. Patients must harbor the 1 of the 2 common EGFR mutations clearly associated with EGFR-TKI sensitivity (i.e., 19Del and L858R) as well as MET overexpression and/or amplification. MET overexpression and amplification must be confirmed by the central laboratory.
  6. No prior systemic anticancer therapy (including chemotherapy, radiotherapy, biological therapy, immunotherapy, or any investigational drugs) for locally advanced or metastatic NSCLC, and the participant is not amenable to curative surgery or radiotherapy. For patients with recurrent disease following prior surgery, if prior adjuvant chemo/radiotherapy, neoadjuvant chemo/radiotherapy, or definitive chemoradiotherapy for advanced disease was received, disease progression should have occurred ≥ 6 months after the completion of the last treatment.
  7. Presence of at least one measurable lesion at baseline according to RECIST v1.1. The target lesion must not have received prior irradiation, or if previously irradiated, must show documented evidence of disease progression after radiotherapy. Brain metastases cannot be selected as target lesions.
  8. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
  9. Life expectancy ≥ 3 months.
  10. Adequate bone marrow reserve or organ function..
  11. Women of childbearing potential must use highly effective contraception. Women of childbearing potential must have a negative blood pregnancy test within 7 days before the first dose. Any male or female participant of childbearing potential must agree to use highly effective contraception throughout the study period and for 6 months after the last dose.

Exclusion Criteria:

  1. Prior treatment with any EGFR inhibitor or MET inhibitor.
  2. Concomitant driver alterations such as ALK, ROS1, RAS, BRAF, RET, and HER2 for which approved targeted therapies are clinically available, if the Investigator judges that the patients cannot benefit from this trial due to the concomitant alteration; or other alterations (e.g., those with substantial clinical evidence supporting a better intervention for the mutation) that, in the Investigator's judgment, preclude benefit from this trial..
  3. Prior antineoplastic therapy within 2 weeks prior to the first dose of study drug, including hormonal therapy, biologic therapy, immunotherapy (including but not limited to anti-PD-1/PD-L1 antibodies, anti-CTLA-4 antibodies, cellular immunotherapy, etc.), local infusion of antineoplastic agents, or Chinese herbal medicines and/or proprietary Chinese patent medicines with approved/intended indications for the treatment of lung cancer.
  4. Prior local radiotherapy (including radionuclide therapy such as strontium-89) within 2 weeks before the first dose of study drug; or, within 4 weeks before randomization, received bone marrow irradiation exceeding 30% or extensive-field radiotherapy..
  5. Clinically uncontrolled (requiring paracentesis or drainage) malignant pleural effusion, ascites, or pericardial effusion within 2 weeks prior to the first dose of study drug.
  6. Major surgical procedure or significant traumatic injury within 4 weeks prior to the first dose of study drug, or anticipated need for major surgery during the study period. Minor clinical procedures such as vascular access placement and core/needle biopsies are permitted.
  7. Presence of leptomeningeal carcinomatosis; presence of spinal cord compression; or symptomatic and unstable brain metastases, unless the participant has completed definitive treatment, has achieved neurological stability for at least 2 weeks prior to randomization, and requires no corticosteroids or anticonvulsants. Asymptomatic patients with brain metastases (e.g., without neurological deficits, seizures, or other typical signs/symptoms of central nervous system [CNS] metastasis) may be enrolled if the investigator assesses that there is no indication for immediate definitive intervention.
  8. Use of strong CYP3A4 inducers within 2 weeks prior to the first dose of study drug, or inability to discontinue strong CYP3A4 inducers during the study period.
  9. History of autoimmune diseases, immunodeficiency disorders (including positive HIV serology), other acquired or congenital immunodeficiency diseases, or history of solid organ or bone marrow transplantation.
  10. Active infection (e.g., the participant is receiving anti-infective therapy).
  11. Severe or uncontrolled cardiovascular diseases requiring medical treatment.
  12. History of hypersensitivity to the active or inactive excipients of osimertinib, gumarontinib/placebo, or chemotherapy agents (pemetrexed and cisplatin/carboplatin), or to drugs of similar chemical structure or class; contraindications to chemotherapy agents (pemetrexed and cisplatin/carboplatin).
  13. Failure to adequately recover from toxicities and/or complications resulting from any prior interventions prior to treatment initiation (i.e., not recovered to Grade ≤ 1, excluding fatigue or alopecia).
  14. Current diagnosis of other malignancies or a history of other active malignancies within 5 years prior to the first study treatment, with the exception of clinically cured localized neoplasms (e.g., basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder carcinoma, prostate carcinoma in situ, cervical carcinoma in situ, breast carcinoma in situ, or papillary thyroid carcinoma).
  15. Definite prior history of neurological or psychiatric disorders, including epilepsy or dementia.
  16. Pregnant or lactating women.
  17. Participation in another investigational drug clinical trial and receipt of investigational drug within 3 weeks prior to the first dose of study drug.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Arm A

Glumetinib 300 mg orally once daily (QD) + Osimertinib 80 mg orally QD,every 3 weeks

Glumetinib 300 mg QD orally under fasting conditions

Administered orally at a dose of 80 mg QD orally

Comparatore placebo: Arm B

Placebo 300 mg orally QD + Osimertinib 80 mg orallyQD,every 3 weeks

Administered orally at a dose of 80 mg QD orally

Placebo 300 mg QD orally under fasting conditions

Comparatore attivo: Arm C

Osimertinib 80 mg QD and platinum-based chemotherapy Osimertinib 80 mg in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.

Administered orally at a dose of 80 mg QD orally

Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.

Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
FS as assessed by IRC
Lasso di tempo: Up to approximately 42 months after the first patient is enrolled

Progression-free survival (PFS) using IRC as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)

Up to approximately 42 months after the first patient is enrolled

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
ORR as assessed by IRC
Lasso di tempo: Up to approximately 42 months after the first patient is enrolled

Objective response rate (ORR) as assessed by IRC

Up to approximately 42 months after the first patient is enrolled
DCR as assessed by IRC
Lasso di tempo: Up to approximately 42 months after the first patient is enrolled

Disease control rate (DCR) as assessed by IRC

Up to approximately 42 months after the first patient is enrolled
DOR as assessed by IRC
Lasso di tempo: Up to approximately 42 months after the first patient is enrolled

Duration of Response (DOR) as assessed by IRC

Up to approximately 42 months after the first patient is enrolled
TTR as assessed by IRC
Lasso di tempo: Up to approximately 42 months after the first patient is enrolled

Time to Response (TTR) as assessed by IRC

Up to approximately 42 months after the first patient is enrolled
PFS as assessed by Investigator
Lasso di tempo: Up to approximately 42 months after the first patient is enrolled

PFS as assessed by Investigator

Up to approximately 42 months after the first patient is enrolled
ORR as assessed by Investigator
Lasso di tempo: Up to approximately 42 months after the first patient is enrolled

ORR as assessed by Investigator

Up to approximately 42 months after the first patient is enrolled
DCR as assessed by Investigator
Lasso di tempo: Up to approximately 42 months after the first patient is enrolled

DCR as assessed by Investigator

Up to approximately 42 months after the first patient is enrolled
DOR as assessed by Investigator
Lasso di tempo: Up to approximately 42 months after the first patient is enrolled

DOR as assessed by Investigator

Up to approximately 42 months after the first patient is enrolled
TTR as assessed by Investigator
Lasso di tempo: Up to approximately 42 months after the first patient is enrolled

TTR as assessed by Investigator

Up to approximately 42 months after the first patient is enrolled
OS
Lasso di tempo: Up to approximately 42 months after the first patient is enrolled

Overall Survival (OS)

Up to approximately 42 months after the first patient is enrolled
Safety
Lasso di tempo: Up to approximately 42 months after the first patient is enrolled

Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs), the other safety variables including physical examination, vital signs and laboratory examinations.

Up to approximately 42 months after the first patient is enrolled
PK parameters
Lasso di tempo: Up to approximately 42 months after the first patient is enrolled

Plasma concentration of Glumetinib

Up to approximately 42 months after the first patient is enrolled

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

31 dicembre 2026

Completamento primario (Stimato)

30 aprile 2029

Completamento dello studio (Stimato)

31 agosto 2030

Date di iscrizione allo studio

Primo inviato

16 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

16 novembre 2026

Primo Inserito (Effettivo)

20 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

20 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

16 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi